Home | About the eMC | Help | Mobile
eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
Advanced search
Get Medicines Compendium UK app here

Pfizer Consumer Healthcare
Vanwall Road, Maidenhead, Berks, SL6 4UB
Telephone: +44(0)1628 692 002
Fax: +44(0)1628 414 728
Medical Information Direct Line: 0845 111 0151
Medical Information e-mail: carelineuk@pfizer.com
Customer Care direct line: 0845 111 0151
Medical Information Fax: +44(0)1628 414 728

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?
Summary of Product Characteristics last updated on the eMC: 08/09/2011
SPC Anadin Extra Soluble Tablets

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 08/09/2011 and displayed until Current
Reasons for adding or updating:
  • Change to section 6. 3 - Shelf Life
  • Change to section 10 date of revision of the text
Date of revision of text on the SPC:   01-Sep-2011
Legal Category:   GSL
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company
The shelf life of the product has been reduced from 3 years to 2 years due to an out of specification result for a batch of tablets under routine stability testing.
Updated on 06/05/2010 and displayed until 08/09/2011
Reasons for adding or updating:
  • Change to section 7 - Marketing Authorisation Holder
  • Change to section 10 date of revision of the text
  • Company name change or merger
  • Change to MA holder contact details
Date of revision of text on the SPC:   27-Apr-2010
Legal Category:   GSL
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company
Change in Marketing Authorisation Holder name and address.
Updated on 21/01/2008 and displayed until 06/05/2010
Reasons for adding or updating:
  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and Lactation
  • Change to section 4.9 - Overdose
  • Change to section 6.2 - Incompatibilities
Date of revision of text on the SPC:   01/2008
Legal Category:   GSL/P
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company
 
 
 
To update sections 2; 4.2; 4.4; 5.4; 4.6; 4.9; 6.2 of the SPC to bring in line with other Wyeth products containing the same active ingredients
Updated on 24/07/2006 and displayed until 21/01/2008
Reasons for adding or updating:
  • Change to section 4.9 - Overdose
Date of revision of text on the SPC:   07/2006
Legal Category:   GSL
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company
section 4.9 overdose amended to reflect changes for symptoms and management of all the active ingredients (aspirin/paracetamol/caffeine)
Updated on 17/03/2006 and displayed until 24/07/2006
Reasons for adding or updating:
  • Change to section 6. 5 - Nature and Contents of Container
  • Change to section 10 (date of (partial) revision of the text
Updated on 26/08/2005 and displayed until 17/03/2006
Reasons for adding or updating:
  • Change to section 6. 5 - Nature and Contents of Container
  • Change to section 10 (date of (partial) revision of the text
Updated on 12/01/2005 and displayed until 26/08/2005
Reasons for adding or updating:
  • New SPC for eMC ie an SPC for an existing product, but one that is new for the eMC

Active Ingredients/Generics

 
  paracetamol
  aspirin
  caffeine citrate